As analysts monitor volatile markets in recent weeks they have updated their price targets on shares of Seattle Genetics, Inc. (NASDAQ:SGEN). Based on the latest notes released to investors, 2 analysts have issued a rating of buy, 4 analysts outperform, 10 analysts hold, 1 analysts underperform and 0 analysts sell.

Latest broker research notes issued:

03/15/2017 Oppenheimer began new coverage on Seattle Genetics, Inc. giving the company a perform rating.

02/13/2017 Seattle Genetics, Inc. had its neutral rating reiterated by analysts at Credit Suisse. They now have a USD 66 price target on the stock.

02/10/2017 Seattle Genetics, Inc. was downgraded to underperform by analysts at Bank of America Merrill Lynch.

12/29/2016 Seattle Genetics, Inc. had its neutral rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 43 price target on the stock.

12/27/2016 Seattle Genetics, Inc. had its buy rating reiterated by analysts at Needham & Company. They now have a USD 72 price target on the stock.

11/29/2016 Seattle Genetics, Inc. was downgraded to equal-weight by analysts at Barclays. They now have a USD 70 price target on the stock.

10/21/2016 Seattle Genetics, Inc. had its outperform rating reiterated by analysts at Leerink Swann. They now have a USD 62 price target on the stock.

10/10/2016 Seattle Genetics, Inc. had its outperform rating reiterated by analysts at RBC Capital. They now have a USD 62 price target on the stock.

09/15/2016 Seattle Genetics, Inc. was upgraded to neutral by analysts at Goldman Sachs. They now have a USD 47 price target on the stock.

09/07/2016 Morgan Stanley began new coverage on Seattle Genetics, Inc. giving the company a overweight rating. They now have a USD 60 price target on the stock.

07/27/2016 Seattle Genetics, Inc. had its neutral rating reiterated by analysts at SunTrust. They now have a USD 38 price target on the stock.

02/10/2016 Seattle Genetics, Inc. had its neutral rating reiterated by analysts at JP Morgan. They now have a USD 43 price target on the stock.

02/10/2016 Seattle Genetics, Inc. had its neutral rating reiterated by analysts at Piper Jaffray. They now have a USD 33 price target on the stock.

08/25/2015 Seattle Genetics, Inc. had its buy rating reiterated by analysts at William Blair.

08/03/2015 Seattle Genetics, Inc. had its market perform rating reiterated by analysts at Cowen. They now have a USD 40.5 price target on the stock.

The share price of Seattle Genetics, Inc. (NASDAQ:SGEN) was down -0.03% during the last trading session, with a day high of 67.30. 1028309 shares were traded on Seattle Genetics, Inc.s last session.

The stocks 50 day moving average is 64.32 and its 200 day moving average is 59.50. The stocks market capitalization is 9.51B. Seattle Genetics, Inc. has a 52-week low of 32.40 and a 52-week high of 75.36.

Receive Seattle Genetics, Inc. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics, Inc. with MarketBeat.com's FREE daily email newsletter.

See the original post here:
Seattle Genetics, Inc. (NASDAQ:SGEN) Valuation According To Analysts - UK Market News